Harmony Biosciences Strengthens Executive Team and Board

Appoints Peter Anastasiou as Chief Operating Officer, adds Troy Ignelzi to Board, and nominates Geno J. Germano for election

Apr. 2, 2026 at 12:05pm

Got story updates? Submit your updates here. ›

Harmony Biosciences Holdings, Inc. has announced several key changes to its executive team and board of directors. The company has appointed Peter Anastasiou as Chief Operating Officer, added Troy Ignelzi to its Board of Directors, and nominated Geno J. Germano for election to the Board at the 2026 Annual Meeting of Shareholders.

Why it matters

These moves are part of Harmony Biosciences' efforts to strengthen its leadership team and board as the company focuses on its next phase of growth. The additions of experienced industry veterans like Anastasiou, Ignelzi, and Germano are expected to help Harmony advance its mission of bringing innovative treatments to patients with rare neurological diseases.

The details

As Chief Operating Officer, Anastasiou will oversee operational execution across the organization, supporting Harmony's growth and advancing key strategic priorities. Ignelzi, an experienced executive with expertise in finance, operations, and corporate governance, will join the Board, while Germano, a 35-year pharmaceutical industry veteran, has been nominated for election to the Board.

  • Anastasiou's appointment as Chief Operating Officer is effective immediately.
  • Ignelzi has been appointed to the Board and will stand for re-election at Harmony's 2026 Annual Meeting of Shareholders.
  • Germano has been nominated for election to the Board at Harmony's 2026 Annual Meeting of Shareholders.

The players

Peter Anastasiou

Newly appointed Chief Operating Officer of Harmony Biosciences. He previously served on Harmony's Board of Directors and has over three decades of experience building and leading biotechnology organizations.

Troy Ignelzi

Newly appointed member of Harmony Biosciences' Board of Directors. He is an experienced executive with expertise in finance, operations, business development, and corporate governance, having led and advised multiple public and private biotechnology companies.

Geno J. Germano

Nominated for election to Harmony Biosciences' Board of Directors. He is a 35-year veteran of the pharmaceutical and life sciences industry with extensive experience developing and commercializing medicines across a broad range of therapeutic areas.

Jeffrey M. Dayno, M.D.

President and Chief Executive Officer of Harmony Biosciences.

Antonio Gracias

Director of Harmony Biosciences since September 2017, who has advised the Board that he will not stand for re-election at the 2026 Annual Meeting of Shareholders.

Got photos? Submit your photos here. ›

What they’re saying

“These moves reflect our continued focus on strengthening our team to support Harmony's next phase of growth.”

— Jeffrey M. Dayno, M.D., President and Chief Executive Officer of Harmony Biosciences

What’s next

Harmony Biosciences will hold its 2026 Annual Meeting of Shareholders, where shareholders will vote on the election of Geno J. Germano to the Board of Directors.

The takeaway

Harmony Biosciences is bolstering its leadership team and board with experienced industry veterans to support the company's ambitious growth plans and continued focus on bringing innovative treatments to patients with rare neurological diseases.